Relationship Between Serum Resistin Levels and Reduction in Visceral Fat in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07564986

Enrollment

Registered

2026-05-04

Start date

2025-04-01

Completion date

2026-04-27

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity Requiring Bariatric Surgery

Keywords

Resistin, morbid obesity, bariatric surgery, sleeve gastrectomy

Brief summary

This study aims to investigate whether a specific protein in the blood, called resistin, can help doctors predict how much dangerous internal fat a patient will lose following weight loss surgery. Sleeve gastrectomy is a common and effective procedure that reduces the stomach's size to help patients lose weight and improve their metabolic health. Beyond just losing weight, it is vital to reduce visceral fat-the fat stored around internal organs-which is closely linked to inflammation and conditions like Type 2 Diabetes. Resistin is a marker known to contribute to insulin resistance and is typically higher in individuals with significant abdominal fat. By measuring resistin levels before surgery, we want to determine if this protein can serve as a guide to predict a patient's internal fat loss and overall metabolic recovery. Ultimately, this research could help healthcare providers better understand the hormonal changes that occur during weight loss and identify which patients may experience the most significant health improvements after the procedure.

Interventions

PROCEDURELaparoscopic Sleeve Gastrectomy

Laparoscopic Sleeve Gastrectomy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patients aged 18 to 75 * International Classification of Diseases (ICD) code E66 diagnosis (obesity) * Patients who have given consent for sleeve gastrectomy * Patients who are suitable for general anesthesia

Exclusion criteria

* Patients who did not give consent to be included in the study * Patients who are scheduled for surgery other than sleeve gastrectomy

Design outcomes

Primary

Measure	Time frame
Change in body mass index at 8 months	8 months after surgery

Secondary

Measure	Time frame
Change in visseral fat at 8 months	8 months after surgery
Change in basal metabolic rate at 8 months	8 months after surgery

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026